Compare Raymond James Financial, Inc. (RJF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Sanofi SA — how do they compare? Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.1× Raymond James Financial, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Sanofi SA for 94 Days on average.
| RJF | SNY | |
|---|---|---|
Market Cap | $30.51B | $95.18B |
Volume | 1,206,253 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $181.18 | $52.34 |
52-Week Low | $140.89 | $39.51 |
Typical Hold Time | 75 Days | 94 Days |
Enterprise Value | $24.37B | $114.48B |
Dividend Yield | 1.36% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $158.6, up 0.83% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has delivered three consecutive quarterly earnings beats, with Q3 2026 EPS of $3.14 exceeding the $2.93 estimate. Revenue growth has been steady, rising from $10.9B in 2022 to $13.84B in 2025, supported by a robust net income margin of 15.37% and an ROE of 18.48%.
The outlook is balanced: analyst consensus is a 'Hold' with a $184 price target, implying 16% upside, but technical weakness and volatile cash flows from aggressive investing activities pose near-term risks. Long-term growth drivers include wealth management expansion and investment banking recovery, though rising expenses and market volatility remain headwinds.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
